# Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

> **NCT00820911** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 175 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** cyclosporine (reduced exposure) / everolimus
- **DRUG:** AEB071 300 mg b.i.d. / everolimus
- **DRUG:** AEB071 200 mg b.i.d. / everolimus

## Key facts

- **NCT ID:** NCT00820911
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820911, "Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00820911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*